Cowen Downgrades Adamas Pharmaceuticals (ADMS) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Needham & Company Downgrades Adamas Pharmaceuticals (ADMS) to Hold
March 5, 2019 7:35 AM ESTNeedham & Company analyst Serge Belanger downgraded Adamas Pharmaceuticals (NASDAQ: ADMS) from Buy to Hold.
The analyst commented, "Gocovri ended 2018 with 4Q18 sales of $13.3MM (+25%Q/Q) via 5,730 fulfilled Rxs (+21%Q/Q) and was expected to double its market share to ~2% in... More
Mizuho Securities Downgrades Adamas Pharmaceuticals (ADMS) to Underperform
March 5, 2019 6:24 AM ESTMizuho Securities analyst Irina Koffler downgraded Adamas Pharmaceuticals (NASDAQ: ADMS) from Neutral to Underperform with a price target of $5.00 (from $11.00) after guidance was withdrawn.
we believe the launch is likely going even worse than we thoughtWe now model $58.5M in 2019... More